Systemic treatments for high-risk localized prostate cancer

Nature Reviews. Urology
Géraldine PignotDelphine Borchiellini

Abstract

The majority of patients with prostate cancer who later develop lethal metastatic disease have high-risk localized disease at presentation, emphasizing the importance of effective treatment strategies at this stage. Multimodal treatment approaches that combine systemic and local therapies offer a promising strategy for improving the clinical outcomes of patients with high-risk localized prostate cancer. Combinations of neoadjuvant and adjuvant chemotherapy, hormonal therapy, or chemohormonal therapy are considered to be the standard of care in most solid tumours and should be investigated in the future for the treatment of prostate cancer to improve patient outcomes. However, although the combination of androgen deprivation therapy and radiotherapy is a standard of care in high-risk localized or locally advanced prostate cancer, the benefit of chemotherapy or chemohormonal therapy has yet to be demonstrated outside of the metastatic setting. Moreover, the benefit of neoadjuvant and/or adjuvant systemic therapies in combination with radical prostatectomy has not been proved. The development of next-generation hormonal agents, which have been approved for the treatment of castration-resistant prostate cancer, offers further thera...Continue Reading

References

Mar 1, 1997·Urology·F LabrieB Candas
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V D'AmicoMing-Hui Chen
Aug 13, 2003·The Journal of Urology·L H KlotzUNKNOWN Canadian Uro-Oncology Group
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Miljenko V PilepichDavid Grignon
May 5, 2005·JAMA : the Journal of the American Medical Association·Peter C AlbertsenJudith Fine
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Phillip G FebboWilliam K Oh
Dec 31, 2005·The New England Journal of Medicine·Deborah A ZarinNicholas C Ide
Jun 6, 2006·The Lancet Oncology·Edward M MessingUNKNOWN Eastern Cooperative Oncology Group study EST 3886
Oct 11, 2007·Journal of the National Cancer Institute·Henry K TsaiPeter R Carroll
Jan 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mack RoachMiljenko V Pilepich
Jan 22, 2008·The Journal of Urology·Judah FriedmanMaha Hussain
Jan 24, 2008·JAMA : the Journal of the American Medical Association·Anthony V D'AmicoPhilip W Kantoff
Mar 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas W FlaigUNKNOWN Southwest Oncology Group
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric M HorwitzWilliam U Shipley
Dec 2, 2008·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·M SouliéUNKNOWN les membres du sous-comité Prostate du CCAFU
Jun 12, 2009·The New England Journal of Medicine·Michel BollaUNKNOWN EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J ZelefskyPeter T Scardino
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tanya B DorffL Michael Glode

❮ Previous
Next ❯

Citations

Aug 25, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Yogesh M BramhechaJacques Lapointe
Feb 23, 2020·Nature Reviews. Urology·Anthony J Costello
Jan 28, 2021·Cell Death & Disease·Marzia Di DonatoGabriella Castoria
Mar 27, 2020·Trends in Cancer·Vincent Giguère
Apr 6, 2021·Current Opinion in Oncology·Jason K MolitorisZaker Rana
Aug 16, 2021·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·N Benziane-OuaritiniI Latorzeff
Sep 8, 2021·The Prostate·Tsuyoshi MatsudaHideki Sakai

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
biopsy
dissection

Software Mentioned

ENZARAD

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.